Targeted Cancer Therapeutics
Esperance Pharmaceuticals, Inc. is a privately held company developing a new class of targeted anticancer drugs that selectively kill cancer cells without harming normal cells. Targeting occurs through binding to specific receptors on the cell’s surface. Esperance’s drugs target and kill even cells known to be resistant to chemotherapeutic drugs. Esperance and MD Anderson Cancer Center have formed a Strategic Alliance to accelerate clinical development of EP-100 for the treatment of women with ovarian cancer and breast cancer.